CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

by | Mar 30, 2026 | Health

Spread the love
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments